Our 15-year track record in the pharma services sector helps us to map the trends that are driving investment. Pharma contract services are experiencing considerable growth as a result of increased investment in the development of new therapeutic products. Ben Faircloth looks at how the pandemic has accelerated investment, created unprecedented demand, and the impact of supply chain reconfiguration and talent shortages.

Related Insights